Lupin (NSE:LUPIN, BOM:500257) received U.S. Food and Drug Administration approval for its abbreviated new drug application for Sodium Zirconium Cyclosilicate for Oral Suspension in 5-gram and 10-gram packets, according to a Tuesday exchange filing.
The drug is indicated for the treatment of hyperkalemia in adults, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.